Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  ResMed    RMD

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

Trading opportunity

share with twitter share with LinkedIn share with facebook
share via e-mail
Recevoir les alertes
02/15/2013 | 11:07am

ResMed could regain its upward trend after having run out of steam.

According to Surperformance ratings, the group has strong fundamentals,as shown by the business predictability. In addition, analysts have recently revised upward their earnings estimates and now expect a profit of USD 2.19 per share for the current year.

ResMed is in an uptrend in the medium and long term, but the last bearish movement returns close to a major support level (USD 42.8), level corresponding to the 20-week moving average. This threshold, if preserved, will enable to enjoy the bullish movement towards the USD 48.4 resistance.

It seems opportune to take a long position around the USD 42.8 support area with in line of sight the USD 48.4 resistance. A stop loss must be placed under the USD 42.8 support.

© Zonebourse.com 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Recevoir les alertes

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 2 342 M
EBIT 2018 575 M
Net income 2018 385 M
Debt 2018 100 M
Yield 2018 1,48%
P/E ratio 2018 41,82
P/E ratio 2019 30,26
EV / Sales 2018 6,33x
EV / Sales 2019 5,69x
Capitalization 14 719 M
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
ResMed Technical Analysis Chart | RMD | US7611521078 | 4-Traders
Duration : Period : Week
ResMed Technical Analysis Chart | RMD | US7611521078 | 4-Traders